OverviewMultiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review
Section snippets
Statement of Search Strategies Used and Sources of Information
The following resources were checked for existing systematic reviews published from 2010 to October 2013: National Guideline Clearinghouse, National Health and Medical Research Council, New Zealand Guidelines Group, American Society of Clinical Oncology (ASCO), National Institute for Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), European Society of Radiotherapy
Literature Search
The following resources were checked for relevant existing systematic reviews that were published from 2010 to October 2013: National Guideline Clearinghouse, National Health and Medical Research Council, New Zealand Guidelines Group, American Society of Clinical Oncology (ASCO), National Institute for Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), European Society
Literature Search Results
In total, 12 systematic reviews [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16] were relevant and met the preplanned inclusion criteria. However, none of them used the same study selection criteria as ours. Thus, these 12 reviews were not discussed further. However, a check of the included studies in these systematic reviews was carried out.
Of 8663 citations identified for original studies, 8301 articles were excluded after reviewing the titles and abstracts and 52 met our
Diagnostic Accuracy Outcome
In the Komai et al. study [56], the sensitivity and specificity of MPMRI to detect CSPC was 86% (95% confidence interval 78–94) and 72% (95% confidence interval 67–78), respectively (Table 2).
In the Abd-Alazeez et al. study [58], each half of the prostate from every patient was treated as one sample size when calculating diagnostic outcomes. When a prostate imaging-reporting and data (PI-RAD) threshold of ≥4 of 5 scores was used for positive MRI results compared with that of PI-RAD ≥3 of 5
Diagnostic Accuracy Outcomes
The overall sensitivity for MPMRI to identify CSPC ranged from 68 to 100% and specificity ranged from 41 to 91% in three studies [61], [65], [66] (Table 2). In the Hoeks et al. study [61], the sensitivity and negative predictive value for MPMRI and MPMRI followed by targeted biopsy were similar and high (92% versus 93% and 94% versus 96%, respectively), but the specificity and positive predictive value were different (41% versus 91%; 33% versus 87%, respectively).
In the Abd-Alazeez et al. study
Discussion
This systematic review showed that in biopsy-naive patients with an elevated risk of prostate cancer (prevalence of 21–30% for CSPC), 6–32% of true CSPC patients were falsely diagnosed negative and 28–79% of non-CSPC patients were falsely diagnosed positive after MPMRI examination; in patients with MPMRI-positive results, 50–76% were falsely diagnosed positive; in patients with MPMRI-negative results, 6–17% were falsely diagnosed negative (Table 2). Between 2 and 13% of patients were diagnosed
Conclusions
Based on the existing evidence, we would not recommend MPMRI followed by targeted biopsy as a standard care in biopsy-naive patients with an elevated risk of prostate cancer (according to PSA levels and/or nomograms). In patients who had a prior negative TRUS-guided systematic biopsy and show a growing risk of having CSPC (e.g. continued significant rise in PSA), MPMRI followed by targeted biopsy may be helpful to detect more CSPC cases as opposed to a repeat TRUS-guided systematic biopsy.
Conflicts of Interest
MH received grants from Sentinelle Medical Company for prostate coil evaluation and is one of the principal investigators in several clinical trials related to MRI application in prostate research. AL received more than $5000 totally in a single year to act in a consulting capacity from Elekta and GE and is one of the principal investigators in several clinical trials related to MRI application in prostate research.
Acknowledgements
The authors would like to thank W. Hijazi for his contribution towards the data audit and members from the MRI in Prostate Cancer Guideline Development Group in Ontario (G. Bauman, R. Breau, J. Chin, W. Chu, J. Dobranowski, S. Ghai, K.S. Jhaveri, L. Klotz, D. Langer, B. Shayegan) for their comments on the early draft of this project.
References (98)
- et al.
Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies
J Urol
(2013) - et al.
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen
Eur Urol
(2014) - et al.
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review
Eur Urol
(2013) - et al.
The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: a meta-analysis
Acad Radiol
(2014) - et al.
A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer
Eur J Radiol
(2010) - et al.
A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion
J Urol
(2011) - et al.
Clinical application of a 3D ultrasound-guided prostate biopsy system
Urol Oncol
(2011) - et al.
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging
J Urol
(2011) - et al.
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging
J Urol
(2011) - et al.
Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients
Eur J Radiol
(2011)
Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients
Eur Urol
Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion
Urology
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer
J Urol
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer
J Urol
Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer
J Urol
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy
Eur Urol
Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study
J Urol
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy
J Urol
A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial
Eur Urol
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies
Eur Urol
Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers
Eur Urol
Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies
J Urol
Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies
Magn Reson Imaging
A negative multi-parametric MRI can rule out up to 97% of clinically significant prostate cancer
J Urol
Multi-parametric magnetic resonance imaging can detect prostate cancers missed by transrectal 12-core biopsy with high accuracy
J Urol
Hard to detect prostate cancer diagnosed by targeted biopsy using combined T2 weighted and diffusion weighted magnetic resonance imaging
J Urol
The role of multiparmetric MRI in men with negative biopsy and elevated PSA – can it rule out clinically significant disease?
J Urol
What burden of prostate cancer can radiologists rule-out on multi-parametric MRI? An analysis based on template prostate mapping biopsies as the reference standard
J Urol
Magnetic resonance image-guided prostate biopsy versus transperineal template prostate biopsy in the diagnosis of clinically significant prostate cancer
J Urol
The ability of MRI guided biopsy to detect clinically significant prostate cancer: a systematic review
J Urol
Value of targeted biopsy in detecting prostate cancer using an office-based MR-US fusion device
J Urol
Gleason score upgrading on MRI/ultrasound fusion guided prostate biopsy versus systematic 12-core trus biopsy
J Urol
Prospective evaluation of MRI-ultrasound fusion biopsy to diagnose prostate cancer in men with prior negative biopsies
J Urol
Targeted biopsy with MRI-ultrasound fusion
J Urol
Magnetic resonance imaging detects significant prostate cancer and could be used to reduce unnecessary biopsies: initial results from a prospective trial
J Urol
First round of trans-rectal targeted biopsies with magnetic resonance imaging/ultrasound-fusion images versus conventional ultrasound-guided biopsies for the diagnosis of localised prostate cancer
J Urol
Enhanced tumour sampling and Gleason grading through fusion of MRI to 3D transrectal ultrasound (TRUS) biopsy
J Urol
Contemporary image-guided targeted prostate biopsy better characterizes cancer volume, Gleason grade and its 3D location compared to systematic biopsy
J Urol
Magnetic resonance imaging guided prostate biopsy versus systematic 14-core prostate biopsy including anterior samplings in detecting significant cancer and assessing cancer aggressiveness
J Urol
Magnetic resonance imaging targeted prostate biopsy with 3-dimensional ultrasound tracking system in comparative analysis to systematic random biopsy on 131 consecutive patients with prebiopsy magnetic resonance imaging
J Urol
Multiparametric MRI can improve the detection rate of prostate cancer and updated the Gleason score at repeated biopsy
J Urol
MRI-targeted TRUS-guided transperineal fusion biopsy is significantly superior to systematic transrectal TRUS-biopsy
J Urol
MRI-ultrasound fusion targeted prostate biopsy: the importance of biopsying outside the MRI lesion
J Urol
Targeted prostate biopsy: are systematic biopsies still necessary?
J Urol
The efficiency of MRI/US fusion targeted prostate biopsies in finding clinically significant prostate cancer compared to standard template biopsy
J Urol
Multiparametric MRI characteristics of patients upgraded by MRI/ultrasound fusion guided biopsy across PSA-based cutoffs
J Urol
Prostate imaging (multi-parametric MRI and prostate histoscanning) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation – the PICTURE study
J Urol
Canadian Cancer Statistics 2014
Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate – a 4-year experience
Urology
Cited by (34)
Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI
2019, Urologic Oncology: Seminars and Original InvestigationsMultiparametric (mp) MRI of prostate cancer
2018, Progress in Nuclear Magnetic Resonance SpectroscopyCitation Excerpt :The potential of MRI for prostate imaging has improved by combining anatomical and functional imaging methods, known as multiparametric MRI (mpMRI) [35–38]. The reported specificity of mpMRI of the prostate is up to 90% with a negative predictive value (NPV) of around 85% [35–38]. This article reviews the technical aspects of mpMRI and highlights its role in PCa detection and evaluation of aggressiveness as well as its role in a pre-biopsy setting.
3-D Quantitative Dynamic Contrast Ultrasound for Prostate Cancer Localization
2018, Ultrasound in Medicine and BiologyCitation Excerpt :Comparison of the performance of 3-D DCE-US with that of mpMRI is difficult because of the large range in Se. ( 68%–94%) and Sp. (21%–70%) reported in studies involving biopsy naive patients (Ahmed et al. 2017; Haider et al. 2016). We recommend performing a study that applies the two techniques in the same patient group to evaluate the differences.
How to conduct a high-quality systematic review on diagnostic research topics
2018, Surgical OncologyCitation Excerpt :The patient characteristics should be similar across different index tests being compared. The index test(s) should not be the reference standard or part of the reference standard to avoid incorporation bias [15] (e.g., any papers where the reference standard included MPMRI, which was the index test in our example, were excluded [7]). Studies with at least one outcome of interest should be included.
Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases
2017, Asian Journal of Urology